Y-mAbs Therapeutics (YMAB) Short Interest Ratio & Short Volume → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free YMAB Stock Alerts $16.26 -0.24 (-1.45%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Y-mAbs Therapeutics Short Interest DataCurrent Short Volume2,100,000 sharesPrevious Short Volume2,170,000 sharesChange Vs. Previous Month-3.23%Dollar Volume Sold Short$30.87 millionShort Interest Ratio / Days to Cover5.3Last Record DateMarch 15, 2024Outstanding Shares43,780,000 sharesFloat Size33,070,000 sharesShort Percent of Float6.35%Today's Trading Volume270,332 sharesAverage Trading Volume364,047 sharesToday's Volume Vs. Average74% Short Selling Y-mAbs Therapeutics ? Sign up to receive the latest short interest report for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatYMAB Short Interest Over TimeYMAB Days to Cover Over TimeYMAB Percentage of Float Shorted Over Time Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. Y-mAbs Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20242,100,000 shares $30.87 million -3.2%6.4%5.3 $14.70 2/29/20242,170,000 shares $36.24 million -1.4%6.6%5.6 $16.70 2/15/20242,200,000 shares $35.20 million -2.2%6.7%6.2 $16.00 1/31/20242,250,000 shares $28.78 million +5.6%6.8%7.3 $12.79 1/15/20242,130,000 shares $20.55 million -7.8%6.4%8.3 $9.65 12/31/20232,310,000 shares $15.75 million +6.9%6.9%11.3 $6.82 Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20232,160,000 shares $14.32 million -13.3%6.5%10.6 $6.63 11/30/20232,490,000 shares $15.46 million -2.4%7.4%13.7 $6.21 11/15/20232,550,000 shares $13.39 million +2.0%7.6%14.9 $5.25 10/31/20232,500,000 shares $13.35 million -4.2%7.6%13.7 $5.34 10/15/20232,610,000 shares $13.83 million -2.6%7.9%13.6 $5.30 9/30/20232,680,000 shares $14.61 million -2.9%8.1%14.9 $5.45 9/15/20232,760,000 shares $13.77 million +6.2%8.4%14.6 $4.99 8/31/20232,600,000 shares $13.18 million -17.2%7.9%11.9 $5.07 8/15/20233,140,000 shares $17.90 million +52.4%9.5%12.8 $5.70 7/31/20232,060,000 shares $12.55 million +6.7%6.1%7 $6.09 7/15/20231,930,000 shares $13.68 million +7.2%5.8%6.3 $7.09 6/30/20231,800,000 shares $12.22 million +2.3%5.5%5.1 $6.79 6/15/20231,760,000 shares $14.10 million +6.7%5.3%2.4 $8.01 5/31/20231,650,000 shares $13.41 million -8.3%5.0%2.3 $8.13 5/15/20231,800,000 shares $18.50 million -2.7%5.5%2.4 $10.28 4/30/20231,850,000 shares $11.08 million +3.4%5.6%2.6 $5.99 4/15/20231,790,000 shares $11.71 million -28.4%5.4%2.6 $6.54 3/31/20232,500,000 shares $12.53 million +26.9%7.6%3.7 $5.01 3/15/20231,970,000 shares $6.64 million +10.7%5.6%6.3 $3.37 2/28/20231,780,000 shares $6.76 million -3.3%5.0%4.7 $3.80 2/15/20231,840,000 shares $7.91 million -5.2%5.2%4.7 $4.30 1/31/20231,940,000 shares $8.71 million +1.0%5.5%4 $4.49 1/15/20231,920,000 shares $9.16 million -0.5%5.5%2.8 $4.77 12/30/20221,930,000 shares $9.42 million +14.2%5.5%2.8 $4.88 12/15/20221,690,000 shares $8.75 million -1.7%4.8%2.4 $5.18 11/30/20221,720,000 shares $7.69 million +17.0%4.9%2.7 $4.47 11/15/20221,470,000 shares $6.56 million -52.3%4.2%2.4 $4.46 10/31/20223,080,000 shares $11.12 million -17.0%8.7%5.8 $3.61 10/15/20223,710,000 shares $53.50 million -1.6%10.5%13.5 $14.42 9/30/20223,770,000 shares $54.36 million -2.3%10.7%13.5 $14.42 9/15/20223,860,000 shares $55.97 million +2.1%10.9%13.6 $14.50 8/31/20223,780,000 shares $60.78 million +1.1%10.7%11.5 $16.08 8/15/20223,740,000 shares $70.39 million +5.4%10.6%10.5 $18.82 7/31/20223,550,000 shares $55.34 million +2.9%10.1%8.3 $15.59Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… YMAB Short Interest - Frequently Asked Questions What is Y-mAbs Therapeutics' current short interest? Short interest is the volume of Y-mAbs Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 2,100,000 shares of YMAB short. 6.35% of Y-mAbs Therapeutics' shares are currently sold short. Learn More on Y-mAbs Therapeutics' current short interest. What is a good short interest ratio for Y-mAbs Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. YMAB shares currently have a short interest ratio of 5.0. Learn More on Y-mAbs Therapeutics's short interest ratio. Which institutional investors are shorting Y-mAbs Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Y-mAbs Therapeutics: Citadel Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Y-mAbs Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.35% of Y-mAbs Therapeutics' floating shares are currently sold short. Is Y-mAbs Therapeutics' short interest increasing or decreasing? Y-mAbs Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 2,100,000 shares, a decline of 3.2% from the previous total of 2,170,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Y-mAbs Therapeutics' float size? Y-mAbs Therapeutics currently has issued a total of 43,780,000 shares. Some of Y-mAbs Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Y-mAbs Therapeutics currently has a public float of 33,070,000 shares. How does Y-mAbs Therapeutics' short interest compare to its competitors? 6.35% of Y-mAbs Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Y-mAbs Therapeutics: Wave Life Sciences Ltd. (2.45%), Savara Inc (5.09%), OPKO Health, Inc. (31.17%), Applied Therapeutics, Inc. (3.58%), Aerovate Therapeutics, Inc. (5.30%), Aurinia Pharmaceuticals Inc. (8.33%), Nurix Therapeutics, Inc. (13.11%), CureVac (5.31%), Longboard Pharmaceuticals, Inc. (11.26%), Enliven Therapeutics, Inc. (20.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Y-mAbs Therapeutics stock? Short selling YMAB is an investing strategy that aims to generate trading profit from Y-mAbs Therapeutics as its price is falling. YMAB shares are trading down $0.24 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Y-mAbs Therapeutics? A short squeeze for Y-mAbs Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of YMAB, which in turn drives the price of the stock up even further. How often is Y-mAbs Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including YMAB, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Wave Life Sciences Short Interest Data Savara Short Interest Data OPKO Health Short Interest Data Applied Therapeutics Short Interest Data Aerovate Therapeutics Short Interest Data Aurinia Pharmaceuticals Short Interest Data Nurix Therapeutics Short Interest Data CureVac Short Interest Data Longboard Pharmaceuticals Short Interest Data Enliven Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:YMAB) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company